AMETEK Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Sep-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
A conventionally owned public company, AMETEK is best analyzed, in our view, through the serial-acquirer compounding model its dispersed owners are backing rather than through any control dynamic. No shareholder controls the company; index funds, Vanguard near 12.4 percent, BlackRock at 9.2 percent, State Street at 4.1 percent, and Geode at 2.3 percent, hold the largest positions, typical of a large-cap industrial. What this ownership represents, in our assessment, is a stake in one of the industrial sector's premier capital-allocation machines. Over decades, AMETEK has built its business through hundreds of acquisitions of differentiated niche instrument and component companies, applying a decentralized operating model and a well-honed operating system to improve their margins and cash generation, then reinvesting that cash into further acquisitions, a self-reinforcing compounding model. The dispersed base holds management accountable for maintaining acquisition discipline, buying quality niche businesses at sensible prices, improving their performance, and allocating the resulting cash flow effectively. Owning AMETEK is a bet on the durability of this proven model, on management's continued ability to source, price, and improve acquisitions of differentiated businesses, and on the cash-generative quality of a diversified portfolio of niche instruments and components, a compounding proposition grounded in capital-allocation skill rather than in any single product line or end market.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Owners of AMETEK hold a diversified industrial compounder whose value, in our view, is driven by disciplined capital allocation and margin improvement rather than by cyclical growth alone. Generating about 7.4 billion dollars of revenue, the company earns high margins from differentiated niche instruments and components and reinvests its substantial free cash flow into acquisitions, compounding value over time; its holders are predominantly index funds, consistent with a large-cap industrial. In our assessment, the bull case rests on AMETEK's proven serial-acquisition model, which has compounded value across decades, the high margins and cash generation of its differentiated niche businesses, its disciplined operating system that improves acquired companies, its diversification across many end markets, and a strong balance sheet that funds continued acquisitions. The bear case comprises the dependence of the model on continued availability of quality acquisitions at sensible prices, integration risk, sensitivity to industrial and end-market cycles that affect organic growth, competition for acquisitions from other compounders, and a premium valuation that reflects the market's confidence in the model. Shareholders are betting that AMETEK sustains its acquisition discipline and operating excellence, continuing to buy, improve, and integrate differentiated niche businesses while generating strong organic cash flow, compounding earnings and value as it has for decades, in a model whose success depends on capital-allocation skill and operational execution more than on the growth of any single market.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| AMETEK | Brand | Global industrial technology parent |
| FARO | Company | Three dimensional measurement and imaging systems |
| Kern Microtechnik | Company | Ultra precision machining and optical inspection |
| Paragon Medical | Company | Medical components and surgical instrumentation |
| Brookfield Engineering | Brand | Viscometers and rheometers |
| MOCON | Brand | Gas analysis and package testing instruments |
| Haydon Kerk Pittman | Brand | Precision motion control products |
Portfolio Analysis
AMETEK competes not on a consumer brand but on a portfolio of differentiated niche technology businesses, and in our view its strength lies in owning many defensible, high-margin franchises rather than any single dominant one. Under the AMETEK parent operate numerous specialized brands and companies: FARO in three-dimensional measurement and imaging, Kern Microtechnik in ultra-precision machining, Paragon Medical in medical components and surgical instrumentation, Brookfield Engineering in viscometers, MOCON in gas analysis and package testing, and Haydon Kerk Pittman in precision motion control, among many others. Each occupies a defensible niche where specialized technology, engineering, and customer relationships command strong margins and pricing power. The strategic proposition, in our assessment, is to own a diversified collection of differentiated niche businesses, each too specialized to attract broad competition, and to improve them through AMETEK's operating system, creating a portfolio of high-margin, cash-generative franchises. Its competitive strengths are the differentiation and defensibility of its niche products, the diversity of its portfolio across many end markets, its operating discipline, and its capital-allocation skill in continually adding quality businesses. In our view, the company's competitive identity rests on this collection of defensible niches and the operating model that improves them, a strength grounded in differentiation and diversification rather than in scale within any single market, and continually renewed by acquisition.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| AMETEK ★ | N/A | $7.401B FY2025 | Diversified precision technology manufacturer |
| Fortive | N/A | $6.2B FY2025 | Industrial instrumentation and software group |
| Roper Technologies | N/A | $7.6B FY2025 | Asset-light industrial technology compounder |
| Teledyne Technologies | N/A | $6.1B FY2025 | Digital imaging and aerospace electronics supplier |
| Danaher | N/A | $24.6B FY2025 | Life sciences and diagnostics technology group |
Competitive Analysis
Competing across many niche instrument and component markets, AMETEK holds, in our view, a strong competitive position built on differentiation, diversification, and its acquisition-and-improvement model. It competes against other diversified industrial-technology compounders, Fortive, the asset-light Roper Technologies, Teledyne, and the larger Danaher, all of which pursue similar strategies of owning differentiated niche businesses. AMETEK's competitive advantages are the defensibility and high margins of its niche products, its diversification across many end markets that reduces reliance on any single one, its disciplined operating system that improves acquired businesses, and its proven capital-allocation skill in continually adding quality companies. The competitive challenges are the intense competition for acquisitions from other well-capitalized compounders, which can raise prices and reduce returns, sensitivity to industrial cycles that affect organic growth, integration risk, and the difficulty of sustaining a serial-acquisition model at increasing scale. In our assessment, AMETEK competes effectively not by dominating any single market but by owning a diversified portfolio of defensible niches and continually improving and expanding it, a model that has produced durable, compounding returns. Its competitive position rests on differentiation, diversification, and capital-allocation excellence, and sustaining it depends on maintaining acquisition discipline against competing compounders and on continuing to improve the businesses it owns, the enduring requirements of a diversified industrial-technology compounder competing on operating and capital-allocation skill.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| FARO Technologies | $920M | 2025 | Expanded three dimensional measurement and imaging capabilities |
| Kern Microtechnik | N/A | 2025 | Added ultra precision machining and optical inspection |
| Paragon Medical | $1.9B | 2024 | Expanded medical components and surgical instrumentation |
| Navitar | N/A | 2022 | Added customized optical solutions |
Acquisitions Analysis
Acquisitions are not merely part of AMETEK's strategy, they are its defining engine, and in our analysis the company's entire investment case rests on the quality of its serial-acquisition model. Over decades, AMETEK has completed hundreds of acquisitions, deliberately reshaping its portfolio away from commodity operations toward differentiated instruments and engineered components, and it continues this migration with recent deals: the 1.9-billion-dollar Paragon Medical acquisition in 2024 expanded medical components and surgical instrumentation, and 2025 brought the 920-million-dollar FARO Technologies acquisition in three-dimensional measurement and Kern Microtechnik in ultra-precision machining. The model is self-reinforcing: AMETEK buys differentiated niche businesses, applies its operating system to improve their margins and cash generation, and reinvests the resulting cash into further acquisitions. For investors, the key insight is that AMETEK's value creation is fundamentally an acquisition-and-improvement story, and its track record of sourcing, pricing, and improving deals is the core of its franchise. In our assessment, this disciplined serial-acquisition model has been extraordinarily successful, compounding value across decades, and its continuation, buying quality niche businesses at sensible prices and improving them, is what shareholders are ultimately backing. AMETEK's future depends more on sustaining this acquisition discipline and operating excellence than on the organic growth of any single business, making capital-allocation skill its most important attribute.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Evolving through serial acquisition rather than transformative merger, AMETEK's corporate structure, in our view, is that of a deliberately assembled and continually reshaped collection of niche businesses. The company began in 1930 as American Machine and Metals, adopted the AMETEK name in 1960, and from the 1990s made a decentralized acquisition model central to its strategy, joining the NYSE in 1997. Rather than a single defining combination, its structure has been shaped by hundreds of acquisitions and by divestitures that removed slower, lower-margin, and commodity operations, migrating the portfolio toward differentiated instruments and engineered components, with recent additions like Paragon Medical and FARO continuing that shift toward precision technology. It operates a decentralized structure organized into instrument and device groups, letting each niche business run with autonomy while the parent allocates capital. For investors, the structural story is one of continual, disciplined reshaping through acquisition and divestiture rather than episodic transformation. In our assessment, AMETEK's structure, a diversified, decentralized portfolio of differentiated niche businesses continually renewed by acquisition, is the physical embodiment of its compounding model, and its evolution has been a steady migration toward higher-margin, differentiated technology. The company's structure is not static but constantly refreshed, and its future shape will continue to be defined by the acquisitions and divestitures through which it compounds value.
Ownership History
Ownership History Analysis
From a Depression-era metals company to a premier industrial compounder, AMETEK's history, in our view, is fundamentally the story of a capital-allocation model perfected over decades. Founded in 1930 as American Machine and Metals and renamed AMETEK in 1960, the company transformed itself beginning in the 1990s by making a decentralized serial-acquisition model central to its strategy, shifting away from commodity operations toward differentiated niche instruments and engineered components. Over the following decades it completed hundreds of acquisitions, applying its operating system to improve each and reinvesting the resulting cash into further deals, compounding value continuously, and it has extended this migration toward precision technology with recent purchases of Paragon Medical in 2024 and FARO Technologies and Kern Microtechnik in 2025. Generating about 7.4 billion dollars in revenue as a widely held large-cap, AMETEK is one of the industrial sector's most successful compounders. Its history, in our assessment, is not defined by any product or transformative merger but by the disciplined refinement of a serial-acquisition-and-improvement model that has reshaped the company from a commodity manufacturer into a diversified portfolio of high-margin niche franchises, a model whose continued execution, buying and improving differentiated businesses, remains the enduring source of its compounding success.
Ownership Explained
Trading on the NYSE under AME, AMETEK is a widely held industrial-technology company with no controlling shareholder, its largest holders being index funds led by Vanguard and BlackRock. Berwyn, Pennsylvania-based and founded in 1930, the company generates about 7.4 billion dollars of revenue with roughly 22,500 employees. Its business is making differentiated electronic instruments and electromechanical devices across precision niches, spanning measurement, medical components, motion control, and analysis instruments. AMETEK is best known as a serial acquirer and disciplined compounder, having built its portfolio through hundreds of acquisitions, including the recent additions of Paragon Medical and FARO Technologies.
Owned broadly by index funds with no dominant holder, AME offers a claim on one of the industrial sector's most successful serial-acquirer compounders. Ownership means participating in a disciplined operating-and-acquisition model that buys niche instrument and component businesses, improves their margins through the AMETEK operating system, and reinvests the resulting cash flow into further acquisitions. What shareholders are backing is not any single product but a proven capital-allocation machine that has compounded value across decades. The investment case rests on continued disciplined acquisitions, margin improvement, and the cash-generative quality of differentiated niche businesses rather than on cyclical end-market growth alone.